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INTRODUCTION 
Single ring enhancing cystic lesions may occur in several infectious and 
neoplastic diseases of the central nervous system and are the most common 
radiological abnormality seen in patients with acute-onset seizures in India 
and many other developing countries. Histopathological studies in India and in 
other countries revealed that neurocysticercosis (NCC) is the most likely cause 
of these lesions provided they fulfill a rigid set of clinical and radiological 
criteria. A single degenerating cyst is the most frequent finding associated 
with NCC in the Indian subcontinent30.Single cysticercus granuloma measures 
less than 20 mm in diameter, may be associated with cerebral edema not 
severe enough to produce midline shift, and occur in patients with seizures, 
normal neurological status, and no evidence of active systemic disease. When 
these lesions resolve spontaneously, either disappearing or changing into a 
calcified nodule, the diagnosis of NCC is very likely. The second most 
common cause of these CT-detected lesions is tuberculoma; in patients with 
these lesions similar clinical and neuroimaging features are also present.  
In a developing country like ours where both tuberculosis and 
Cysticercosis are common, it is difficult to differentiate between tuberculoma 
and a single cysticercal granuloma. The most interesting feature of these 
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solitary enhancing lesions is their spontaneous disappearance within weeks or 
months. Some lesions "heal" by becoming calcified. These patients require 
only antiepileptic therapy, and this medication may be withdrawn safely after 
the lesion has resolved on CT scanning. In several studies provision of 
anticysticercal drugs has been attempted, but because of conflicting results, 
their role in the management of these single lesions is uncertain. 
Magnetization transfer, a new technique for improving image contrast 
in magnetic resonance (MR) imaging, is based on application of off-resonance 
radio-frequency pulses and observing their effects on MR images, as well as 
measuring the signal intensity with and without application of the pulses (i.e., 
magnetization transfer ratio. MTRs can be used to detect changes in the 
structural status of brain parenchyma that may or may not be visible with 
standard MR techniques. 
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AIM OF THE STUDY 
To study the presentation and natural course of single ring enhancing 
Neurocysticercosis. 
To assess the efficacy of Magnetization Transfer Imaging in differentiating 
Neurocysticercosis from Tuberculoma. 
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REVIEW OF LITERATURE 
Single enhancing lesions visualized on CT scanning are the most common 
radiological abnormality in Indian patients with new-onset seizures[17]. In 
1980, Tandon and Bhargava[48] first reported these lesions; at that time these 
CT-enhancing lesions were presumed to be tuberculoma and often were 
treated with empirical antituberculous drugs.  
Subsequently, histopathological studies of brain tissue biopsy samples have 
suggested that, in majority, single CT-enhancing lesions represent dying 
cysticercal lesions (larval stage of tape-worm Taenia solium). [39] These single 
CT-enhancing lesions often resolve spontaneously.[17] Considerable 
controversy persists about their cause and appropriate management.  
Epidemiology: 
The precise incidence and prevalence of single enhancing CT-documented 
lesions, in India and other parts of the world, are not known. All data available 
in India are from hospital-based studies. Wadia, et al.,[50] studied 150 patients 
with simple partial seizures, and CT scanning revealed single enhancing 
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lesions in approximately 26%. The incidence of these lesions was higher 
among children; 40% of patients were younger than 15 years of age. Misra, et 
al.,[24]from North India, studied 1023 patients with partial seizures and 
obtained plain and contrast-enhanced CT scans in all. A single enhancing CT-
demonstrated lesion was found in approximately 50% of patients (513 
cases).[24] In a study from South India Murthy et al.,[26] reported these CT 
lesions in 23.4% of 2531 patients with all types of epilepsies. Garg and 
Nag[16] observed a higher incidence (72%) of single enhancing lesions in 
children and adolescents when CT scanning was performed after the first 
seizure. 
Although initially it was thought that these lesions are found only in 
individuals from the Indian subcontinent, similar lesions were later reported 
from other parts of the world. Single enhancing lesions are frequently seen in 
Latin American countries and are invariably treated as cysticercal 
granuloma.[8] These lesions have also been reported in studies conducted in 
several developed countries such as Australia, the United States, and the 
United Kingdom.[20,23,47]Wadley, et al.,[51] recently reported a series of six 
patients from United Kingdom with single enhancing lesions. In all six 
patients the referral diagnoses were either tumor or tuberculoma. In the 
majority, the lesions had spontaneously disappeared. These authors concluded 
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that patients harboring single enhancing CT-documented lesions, even in 
nonendemic regions, need careful observation because their lesions may 
disappear spontaneously and patients may be saved from unnecessary 
neurosurgery. 
Radiological Features: 
The characteristic ring or disc-enhancing CT lesions are seen after intravenous 
contrast administration. 
Plain CT scans, at times, 
demonstrate some 
abnormality. The most 
common abnormality 
observed on plain scans 
is irregular low attenuation areas of vasogenic cerebral edema. Infrequently, a 
tiny speck of calcification is demonstrated within the area of hypodensity. 
Using newer-generation CT machines, it is possible to see the outline of 
complete cystic lesion with an extramural nodule.[13] Plain CT scanning may 
not reveal any abnormality.[6,15,17] 
After contrast administration, there is a ring or a homogeneous disclike 
enhancement within the region of hypodensity. The enhancing lesions 
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observed on these CT scans are usually less than 20 mm in diameter; they are 
surrounded by a varying amount of perifocal edema. Occasionally, the edema 
may be severe enough to produce midline shift. An enhancing or a calcified 
eccentric dot (presumed to be a scolex of cysticercal larva) can be seen within 
the ring lesion (above Fig.). Single CT-documented lesions can be seen 
throughout the cerebral hemispheres, more commonly situated superficially in 
the gray matter or at the junction of gray matter and white matter. Parietal 
lobes are the most common location for these lesions. Frontal and occipital 
lobes are the other frequent sites.[6,15,17,31] 
Radiological disappearance of Enhancing lesions: 
The most remarkable feature of single enhancing lesions observed on CT 
scanning is their 
complete 
spontaneous 
disappearance in the 
majority of patients, 
as well as their 
occasional significant reduction in size in others. The edema surrounding the 
lesion is usually the first to resolve. Later, the lesion may disappear 
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completely, leaving no residue, or it may leave a tiny speck of calcification at 
the former site of the lesion. In some patients the granulomatous lesion 
transforms into a calcified nodule.[17,31] (above Fig.) 
Etiopathogenesis: 
Since these lesions were first described, their precise origin has 
remained controversial. Several origins have been postulated, from time to 
time, to explain the cause of these single enhancing lesions. 
 
 
 
 
 
 
 
 
In immunocompromised 
Toxoplasmosis 
CNS lymphoma 
Fungal granuloma 
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Neurocysticercosis 
Tuberculoma 
Uncommon                       
Glioma 
Secondaries 
Cryptic AVM 
Brain abscess 
Sarcoidosis 
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Postictal Phenomenon 
Until recently one of the major points of controversy was whether these 
lesions were cause or effect of the associated seizure disorder. Several 
biochemical and physiological changes occur at the site of abnormal neural 
activity during or following partial seizure. It was thought that the changes 
noted in neurons, blood vessels, and the blood-brain barrier had resulted in 
ring- or disclike enhancement on CT scanning.[18,19] 
Intercranial Tuberculoma 
In initial reports, several authors determined that single enhancing 
lesions were tuberculoma, based on several presumptions. Intracranial 
tuberculoma were common intracranial space-occupying lesions in this part of 
the world. Tuberculoma and tuberculous abscess constituted approximately 10 
to 20% of all intracranial masses. Similar lesions documented on CT scanning 
were often seen in association with tuberculous meningitis. A favorable 
response to empirical antituberculous treatment was observed. Finally, 
tuberculosis is a highly endemic disease in India.[21,48] 
 
16 
 
 
Neurocysticercal Cysts 
A major breakthrough in the understanding of these single CT-enhancing 
lesions came when Chandy, et al.,[5]reported obtaining CT-guided stereotactic 
biopsy samples. Histopathological examination of these brain tissue samples 
showed cysticercal granuloma in the majority of patients. In another study of 
51 patients Rajshekhar, et al.,[39] documented cysticercal granulomas in 25 
patients and tuberculoma in six; in all cases these findings were confirmed. Of 
the remaining 20 patients, 12 patients harbored parasitic granuloma 
(cysticercal lesion not definite), six patients nonspecific inflammation, and 
one patient each had dystrophic calcification and secondary metastasis. The 
authors concluded that the majority of single enhancing CT lesions are caused 
by NCC; however, other diseases such as tuberculoma should always be 
considered in the differential diagnosis. 
Other Diseases Causing Single Enhancing Lesions 
Various other presumptive diagnoses such as glioma, larva-migrans infection, 
microabscess, secondary metastasis, small infarct, focal encephalitis, and 
cryptic AVM have been suggested but none is consistently demonstrated in 
histopathological studies.[17,31] 
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Pathological charecteristics: 
A parenchymal cysticercal cyst of the brain passes through four stages of 
natural evolution.  
After entering in to the brain parenchyma, the parasite develops into a 
"vesicular stage" in which the cysts are viable and elicit very little 
inflammatory response in the surrounding brain tissue. On CT scanning viable 
cysticercal lesions appear as rounded, circumscribed, hypodense lesions, and 
contrast enhancement is absent. After a variable period of time the parasite 
loses its viability either because of aging, inability of larva to become adult, or 
immunological factors particular to the host, and it enters into the next stage.  
The second phase is the "colloidal stage" in which inflammatory changes 
develop in the cyst wall and surrounding brain parenchyma. Transparent 
cystic fluid is replaced by jellylike whitish material, which is surrounded by a 
fibrous capsule. This dying stage of larva is referred to as cysticercal 
granuloma. In this stage, CT scanning demonstrates a ring-enhancing lesion.  
18 
 
Progressive reduction in the size of the cyst and scolex and mineralization of 
cystic fluid lead to development of a "granular-nodular" stage in which the 
larva appears as a disc-enhancing lesion on contrast-enhanced CT.  
In the last "calcific stage" the lesion becomes completely mineralized and 
appears as a hyperdense calcified nodule on plain CT scanning. At this stage 
there is no contrast enhancement and surrounding edema is also absent 
because of abatement of inflammation.[11] 
Rajshekhar, et al.,[34] have attempted to demonstrate the presence of a viable 
parasite within the single CT-enhancing lesions. They performed 
histopathological examination of 43 brain tissue biopsy samples and were 
successful in demonstrating cystic lesions containing parts of an intact or 
degenerated larva in 22 patients. Inflammatory cavitary lesions, in which there 
was no definite evidence of parasite, were observed in 13 patients, whereas 
noncavitary hyalinized fibrous nodules with inflammation were found in the 
remaining eight. Of the 22 specimens in which there was definite evidence of 
cysticercosis, only lesions in two patients were shown to have an entire 
parasite within the granulomatous lesion. It was not possible to predict the 
presence of an intact parasite within the granuloma on the basis of clinical and 
radiological features. 
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In a more recent article, Chacko, et al.,[4] reported that, in a few patients, when 
no intact parasite or parasitic parts were observed within a granuloma, it was 
possible to demonstrate the presence of small ovoid masses corresponding 
morphologically to the intracorporeal vacuoles of a cysticercal larva. These 
structures were found to lie within the cavitary space of granuloma. The 
authors concluded that even the presence of calcareous residues of parasites 
may be the only evidence of cysticercal origin in some of the granulomas. 
Clinical Features: 
The patients in whom CT scanning reveals single enhancing lesions usually 
present with new-onset seizures. The seizures are often partial (motor > 
sensory) with or without secondary generalization. If a lesion is located in the 
occipital lobe, seizure is often preceded by visual aura, and in frontal lobe 
lesions an "adversive attack" is frequently observed. Cases of complex partial 
seizures are rare. Few patients present with partial status epilepticus. Several 
episodes of seizure occur in clusters, within a span of 2 to 3 days. 
Infrequently, Todd paralysis, which resolves within 24 hours, is 
observed.[15,35,50]Another major complaint in patients with single enhancing 
lesions is headache. A large number of patients presenting with seizure 
experience persistent or episodic headache during the interictal period.[15,17] In 
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some patients, severe episodic headache may be the only presenting 
complaint. In these patients the headache can be of such severe intensity so as 
to mimic that of a subarachnoid or an intracerebral hemorrhage. The fundus is 
usually found to be normal. Infrequently, the headache may be part of a frank 
increase in ICP. Patients experience headache, vomiting and papilledema. In 
this variety of headache the enhancing lesions have been noted in subcortical 
locations. Headache and other signs of raised ICP improve after spontaneous 
resolution of the lesion. Oral corticosteroid medication helps to relieve 
headache in the acute stage.[14] Patients in whom CT scanning demonstrates a 
single enhancing lesion in the brainstem invariably suffer headache and 
exhibit other brainstem signs.[22] Focal neurological deficits in the absence of 
seizures are rare and, at times, may be the sole manifestation.[14] 
Diagnosis:- Cysticercal Granuloma and Tuberculoma 
The distinction between cysticercal granuloma and tuberculoma is 
controversial, often associated with single enhancing CT-documented lesions. 
This is because the clinical and imaging features are quite similar; both 
diseases are common in endemic areas and may coexist in the same patient. 
Rajshekhar, et al.,[39] have attempted to differentiate between these two 
entities on the basis of clinical and imaging features. Based on these findings 
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and their experience, Rajshekhar and Chandy[38]suggested that cysticerci are 
usually round in shape, 20 mm or smaller in size, with ring enhancement or a 
visible scolex; cerebral edema severe enough to produce midline shift or focal 
neurological deficit is not seen. Tuberculomas, by contrast, are usually 
irregularly shaped, solid, and greater than 20 mm in size. They are often 
associated with severe perifocal edema and focal neurological deficit[38] .   
 
Diagnostic criteria for cysticercal granuloma* 
Criteria 
clinical 
   seizure (partial or generalized) as initial symptom 
   no persistent raised ICP 
   no progressive neurological deficit 
   no active systemic disease 
CT picture 
   solitary, contrast-enhancing lesion 
   20-mm diameter lesion 
   no severe cerebral edema (no midline shift) 
* As established by Rajshekhar and Chandy (1997).[33,35] 
 
This distinction is important because parenchymal cysticercosis is a benign 
and self-limiting condition, whereas tuberculoma is an active infection 
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requiring prolonged therapy that involves potentially toxic drugs. Several 
authors firmly believe that this vital distinction, based on clinical and imaging 
features, is very difficult to make.[44] In addition to those features suggested by 
Rajshekhar and Chandy,[38] several other imaging features have been 
suggested to differentiate between these two entities. For example, in this 
setup a target lesion (a lesion with central or eccentric nidus of calcification or 
a dot of enhancement) is frequently visualized. In the past, these target lesions 
were considered a pathognomonic feature of CNS tuberculoma.[2] More 
recently, Del Brutto, et al.,[10] reported that visualization of an enhancing 
eccentric dot, which may possibly represent the scolex of cysticercosis, can be 
considered a definite imaging feature of cysticercus origin. 
Magnetic Resonance Imaging.  
Magnetic resonance imaging is frequently performed with the objective of 
differentiating between cysticercal granuloma and tuberculoma. In fact, the 
MR imaging features of both these conditions are also very similar and usually 
not helpful in this differentiation. Investigation entailing T1-weighted MR 
images reveals a low signal center with isointense periphery. Granulomas are 
better visualized on T2-weighted sequences where a low signal ring and high 
signal center are characteristic features. Surrounding edema is also best seen 
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on T2-weighted MR images (above Fig). On contrast-enhanced MR imaging 
studies the granuloma shows marked peripheral enhancement and a low signal 
area in the center.[36] 
 
Serological Studies.  
The two principal serological tests are the enzyme-linked immunosorbent 
assay and the enzyme-linked immunotransfer blot. The latter is regarded as 
more reliable, with a specificity of 100% and a sensitivity of up to 97%, in 
tests of both blood and cerebrospinal fluid. Several authors, however, have 
demonstrated that these tests display poor sensitivity in detecting antibodies in 
cases of single lesions when sensitivity is very low (range 14-45%). Positive 
results obtained with these tests may help in confirming the diagnosis of 
cysticercal granuloma, but negative results cannot be used to exclude a 
diagnosis of cysticercosis.[40,41] 
Diagnostic Criteria. Several diagnostic criteria for NCC have been proposed; 
however, in none of the criteria has the issue of differentiation between 
cysticercal granuloma and tuberculoma been addressed. This is the most 
difficult differentiation clinicians face in the developing countries. These 
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diagnostic criteria are based on clinical, epidemiological, imaging, and 
serological features along with response to anticysticercal drugs.  
During a recent consensus meeting on cysticercosis held in August 2000 in 
Lima, Perú, a panel of experts agreed upon more accurate and stringent 
revised criteria for the diagnosis of neurocysticercosis. 
Chart of diagnostic criteria and degrees of diagnostic certainty for human 
cysticercosis 
Diagnostic criteria and degrees of certainty Criteria 
Absolute criteria  
1. Histologic demonstration of the parasite 
2. Direct visualization of the parasite by funduscopic examination 
3. Evidence of cystic lesions showing the scolex on CT or MRI 
Major criteria  
1. Evidence of lesions suggestive of neurocysticercosis on neuroimaging 
studies 
2. Positive immunologic tests for the detection of anticysticercal antibodies 
3. Plain X-ray films showing “cigarshaped” calcifications in thigh and calf 
muscles 
Minor criteria  
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1. Presence of subcutaneous nodules (without histologic confirmation) 
2. Evidence of punctuate soft-tissue or intracranial calcifications on plain X-
ray. 
3. Presence of clinical manifestations suggestive of neurocysticercosis 
4. Disappearance of intracranial lesions after a trial with anticysticercal drugs 
 
Epidemiologic criteria  
1. Individuals coming from or living in an area where cysticercosis is endemic 
2. History of frequent travel to cysticercosis-endemic areas 
3. Evidence of a household contact with Taenia solium infection 
Degrees of certainty 
Definitive diagnosis  
1. Presence of one absolute criterion 
2. Presence of two major criteria 
3. Presence of one major plus two minor and one epidemiologic criterion 
Probable diagnosis  
1. Presence of one major plus two minor criteria 
2. Presence of one major plus one minor and one epidemiologic criterion 
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3. Presence of three minor plus one epidemiologic criterion 
Possible diagnosis  
1. Presence of one major criterion 
2. Presence of two minor criteria 
3. Presence of one minor plus one. 
Unfortunately, none of the criteria proposed by Del Brutto, et al.,[9,10] seems to 
be helpful in differentiating between these two entities . 
Other Diagnostic Possibilities 
Several other diseases may also pose a diagnostic challenge in patients with a 
single enhancing CT-documented lesion. It is important to assess for the 
presence of a systemic disease such as pulmonary tuberculosis, malignancy, or 
a source of bacterial infection. A small CT-demonstrated enhancing brain 
lesion in an aged individual should arouse great suspicion of secondary 
malignancy and effort should be made to define primary site. When applicable 
(for example, in cases in which there is a history of sexual contact with a high-
risk individual), serological tests for the human immunodeficiency virus 
infection should be performed because several human immunodeficiency virus 
related CNS complications such as toxoplasmosis, CNS lymphoma, and 
various fungal granulomas can present with single enhancing lesions. 
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Enlargement of lesions on follow-up CT scans is not necessarily indicative of 
a neoplastic nature because a small but significant number of single 
cysticercal granuloma may show paradoxical enlargement (exceeding 20 mm 
in diameter) after treatment with anticysticercal drugs.[37] Singh and 
associates[45] reported two patients in whom even enlarged CT-evidenced 
lesions resolved spontaneously. 
Management: 
Until recently, there was no consensus concerning the exact origin of these 
single enhancing lesions in India; thus, a uniform treatment has not been 
practiced. Various physicians continue to treat these lesions differently. 
Antituberculous Treatment 
In few initial series, patients received antituberculous treatment.[50]After 
histopathological demonstration of cysticercal disease origin in a majority of 
patients, as well as evidence of spontaneous resolution of these lesions, 
antituberculous treatment is now infrequently used. 
Anticysticercal Treatment 
In Latin American countries, CT-depicted single enhancing lesions are 
invariably treated either with albendazole or praziquantel. In an uncontrolled 
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study Del Brutto[8] observed early resolution of lesions on CT scans following 
treatment with albendazole. More recently, in a controlled study, Pretell, et 
al.,[28] included 26 patients with single enhancing lesions. The patients were 
openly assigned to receive either single-day praziquantel therapy (three doses 
of 25 mg/kg at 2-hour intervals) or no treatment. In praziquantel-treated 
patients, complete resolution occurred in 11 and partial resolution in two; in 
the remaining patient the lesion was later diagnosed as AVM. Conversely, the 
lesions persisted unchanged in six of 12 patients in the nontreatment group. 
The authors favored routine administration of anticysticercal drugs in patients 
with single enhancing lesions.[28]Although this single-day praziquantel therapy 
has been found particularly useful for single lesions, poor response has been 
noted in those with multiple cysticercal lesions.[29] 
In India, studies involving anticysticercal treatment have provided conflicting 
results. In a placebo-controlled study Padma, et al.,[27]observed that 7-day 
treatment with albendazole did not hasten the resolution of CT-documented 
lesions. In a different double-blind placebo-controlled study, however, 
Baranwal, et al.,[1] observed a significantly faster and higher incidence of 
complete disappearance of lesions in children who underwent 28-day 
albendazole treatment (15mg/kg/day). The conflicting results of these two 
studies also fueled the controversy of the ideal dosage regimen of albendazole. 
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A comparative study is needed to evaluate 7- or 8-day albendazole treatment 
in a 30-day course in patients with single CT-enhancing lesion. In patients 
with other forms of NCC, Cruz, et al.,[7] have already demonstrated that 8 day 
albendazole treatment is as effective as 15- or 30-day therapy. These authors 
concluded that there is no benefit to extending albendazole treatment beyond 7 
or 8 days. 
Antiepileptic Treatment 
It has been argued that because CT-demonstrated enhancing lesions represent 
dying stages of cysticercal lesion, they require no anticysticercal treatment. 
Because these lesions disappear spontaneously, patients require only 
antiepileptic drugs to control the associated seizure disorder.[12] Chopra, et 
al.,[6] reported on 78 patients who underwent follow-up repeated CT scanning 
within 6 to 12 weeks; in 47 cases complete spontaneous resolution of the 
lesions was observed. Significant reduction in the size of the lesions and 
surrounding cerebral edema occurred in 24 patients; additional repeated CT 
studies revealed either complete disappearance or considerable regression in 
due course. All these patients received antiepileptic drugs only. In the only 
prospective study, Singh, et al.,[46] included 75 patients with single enhancing 
lesions. Follow-up CT scanning conducted after 2 months revealed complete 
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spontaneous disappearance of lesions in 55 patients (73.3%). In 11 patients 
(14.7%) the lesions became calcified. In the remaining nine patients in whom 
the lesions persisted or regressed, another follow-up CT study (after 6 months) 
revealed either complete disappearance or calcification. The majority of 
patients (87%) remained seizure free after 1-year follow-up examination. 
Associated Seizure Disorder 
Enough evidence is available to suggest that the prognosis of associated 
seizure disorder is better in cases in which single enhancing lesions are present 
than in those in which other forms of parenchymal NCC are found; in the 
latter there is very high incidence of seizure recurrence after withdrawal of 
antiepileptic drugs.[3] It has been suggested that patients with CT-documented 
single enhancing lesions do not require conventional prolonged therapy of 2 to 
3 years. Antiepileptic drugs can safely be withdrawn once the lesion has 
disappeared. In a retrospective study, Murthy and Subba Reddy[25] studied 102 
patients in whom CT scanning revealed a single enhancing lesion and in 
whom seizures were present. In 64 patients seizures did not recur once 
antiepileptic treatment was instigated. Twenty-eight patients (27.5%) 
continued to experience seizure recurrence for a median 2-month period 
before spontaneous remission was achieved. In the remaining 10 patients 
31 
 
seizures recurred after albendazole therapy (median period of seizure 
recurrence 8 months). The anti-epileptic drugs were withdrawn in all patients 
after the follow-up CT scan revealed complete resolution of the lesions. After 
withdrawal of antiepileptic drugs, only one patient experienced seizure 
recurrence during the mean follow-up period of 45 months (range 19-101 
months). In this patient in whom seizures recurred, follow-up CT scanning 
revealed a gliotic scar at the site of the enhancing lesion.[25] 
In one review Carpio, et al.,[3] suggested that seizures in patients with CT-
demonstrated single enhancing lesions should be considered as acute 
symptomatic seizure disorder and such patients require antiepileptic treatment 
for the acute-stage period (perhaps for several months, during which the 
inflammatory reaction of the lesion is most active). Once the lesion has 
disappeared, antiepileptic therapy may be gradually withdrawn. If seizures 
recur, the antiepileptic therapy treatment should be reinitiated and the patient 
may be treated for 2 to 3 years. If lesions have become calcified, the 
antiepileptic therapy should be provided for a longer period (2-3 years) before 
being tapered. 
Persistence of Enhancing Lesions: 
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Until recently, if single enhancing lesions did not disappear or regress within a 
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reasonable time period (usually within 6 months), they were viewed with 
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suspicion (Fig. 5). Often alternative diagnoses such as tuberculoma, pyogenic 
abscesses, or metastatic lesions were considered. Some authors have 
contended that "persistence" of lesions indicates that more aggressive 
treatment brain biopsy sampling is necessary.[31] Currently it is very difficult 
to set a cutoff period after which these lesions may be termed persisting. In a 
recent prospective follow-up study, Rajshekhar[32] noted that the longer the 
follow-up period the higher the number of cases in which spontaneous 
disappearance of the granuloma occurred. He observed that at 6 months in 
only 19% of 210 patients had complete resolution occurred whereas at the end 
of 1 year and 2 years, respectively, in approximately 63 and 89% of patients 
CT scans revealed normal findings. Garg and Nag[16] also reported similar 
observations in a retrospective study. They observed that in 16 of 101 patients 
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the lesions did not disappear or regress after 6 months. Additional follow-up 
scans in these 16 patients, however, revealed that the lesion eventually 
calcified in four patients, the ring lesions changed to disc lesion and degree of 
associated edema was considerably less in four, and the lesion persisted 
unchanged in the remaining eight.[16] Although concern is often expressed, in 
none of the prospective and retrospective follow-up studies has either clinical 
deterioration or significant enlargement of lesions been noted.[6,15,25,26,32,46] In 
several uncontrolled series, albendazole therapy has been shown to produce 
complete resolution of persisting lesions.[30,49] 
Role of Neurosurgery: 
The mainstay of treatment in patients with CT-evidenced single enhancing 
lesions is seizure control with antiepileptic drugs. Seizures can often be very 
well controlled. Small cortical granulomas do not require biopsy sampling or 
removal of the lesion because the parasite is in the stage of dying and will 
disappear spontaneously. The principal indications for surgical intervention in 
patients with NCC are treatment of hydrocephalus, the removal of mobile 
intraventricular cysts, spinal cysts, accessible racemose cysts in the basal 
cisterns, and large supratentorial cysts causing mass effects. 
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Stereotactic brain biopsy sampling is often difficult because of the toughness 
and mobility of the cysticercal lesion, and it can also be hazardous because of 
the typical site of lesions at the junction of gray-white matter and possible risk 
of intracerebral hemorrhage. Moreover, because the lesion is benign, obtaining 
a biopsy sample is not justified in every patient. In very rare cases in which a 
lesion enlarges and causes increasing neurological deficit refractory to 
albendazole treatment, other diagnoses such as abscess, tuberculoma, or tumor 
(primary or secondary metastasis) are likely. Later in the course neurosurgery 
may be required. Even in developed countries where these lesions are 
infrequent this same nonsurgical approach has proven successful.[51] 
Initially single enhancing lesions demonstrated on CT scanning were 
presumed to be tuberculoma and were treated with empirical antituberculous 
drugs. Later, histopathological examination of brain tissue biopsy samples 
suggested that, in majority, these lesions are single cysticercal granuloma. 
Tuberculoma may be present in a few of these patients. It is very difficult to 
differentiate cysticercal granuloma from tuberculoma based on clinical and 
radiological characteristics. The authors of several prospective and 
retrospective studies have convincingly demonstrated that, regardless of 
origin, single enhancing CT-documented lesions tend to disappear 
spontaneously. Patients require antiepileptic drugs to prevent seizure 
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recurrence. The role of albendazole or praziquantel in hastening the resolution 
of lesions is uncertain. Antiepileptic drugs may safely be withdrawn after CT 
evidence that the lesion has disappeared. Neurosurgical intervention may be 
considered if lesions increase in size and produce uncontrolled seizure or 
progressive focal neurological deficit. 
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MAGNETIZATION TRANSFER IMAGING: 
 
Introduction: 
Magnetization transfer (MT) in a magnetic resonance imaging (MRI) 
context was first discovered accidentally by Dr Bob Balaban et al. These 
investigators were attempting to perform a spin transfer experiment by 
selective saturation of urea looking for small signal suppression in water. 
Instead, they found a significant loss of image intensity from the proton signal 
in tissue, which did not depend on the specific offset frequency of the 
irradiation. 
This generalized signal suppression, now known as MT, has become accepted 
as an additional way to generate unique contrast in MRI that can be used to 
advantage in a variety of clinical applications. The detailed underlying 
biophysics of MT is quantitatively understood, enabling MT to be optimally 
exploited in MRI. 
HOW MT WORKS? 
Proton MRI detects signal only from mobile protons which have 
sufficiently long T2 relaxation times (i.e. greater than 10 ms) so that spatial 
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encoding gradients can be played out between excitation and acquisition 
before the signal has completely decayed. The T2 of the less mobile protons 
associated with macromolecules and membranes in biological tissues are too 
short (i.e. less than 1 ms) to be detected directly in MRI. However, coupling 
between the macromolecular protons and the mobile or ‘liquid’ protons allows 
the spin state of the macromolecular protons to influence the spin state of the 
liquid protons through exchange processes. As shown in the figure below it is  
 
possible to saturate the macromolecular spins preferentially using an off-
resonance radio frequency pulse. The macromolecular spins have a much 
broader absorption line shape than the liquid spins, making them as much as 
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106 times more sensitive to an  appropriately placed off-resonance irradiation. 
This preferential saturation of the macromolecular spins can be transferred to 
the liquid spins, depending on the rate of exchange between the two spin 
populations, and hence can be detected with MRI. 
Applications in imaging 
Magnetization transfer is more than just a probe into the proton spins 
interactions within tissues. It can be used to provide additional advantageous 
contrast in MR images. One universally agreed upon MT application is in 
magnetic resonance angiography (MRA). MRA uses specific imaging 
sequences to suppress the signal from static tissues while enhancing signal 
from blood by means of inflow or phase effects. The signal contrast between 
the blood and other tissue can always be enhanced by using MT (which need 
not affect blood) to further suppress the background tissue signal. Better 
contrast between blood and tissue leads to better angiograms. The 
improvement produced by MT in MRA is predicted to become even greater at 
higher fields because of the larger MT effect.  
The second major application of MT is characterization of white matter 
disease in the brain, principally multiple sclerosis (MS). MS is a diffuse, 
progressive disease, grossly characterized by the presence of lesions in brain 
white matter tissue with pathological characteristics\ that vary as the lesions 
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evolve. The evolution and history of specific MS lesions is difficult to resolve 
with conventional T1-weighted or T2-weighted MRI, and some lesions are 
unobservable. Using MT imaging for regionof- interest analyses, however, 
MS lesions are more conspicuous and MTR values provide information on 
lesion evolution. More recently, the diffuse characteristics of MS have been 
characterized by plotting the MTR histogram of the whole brain. This process 
indicates that there are significant differences between the MTR ratio of the 
so-called ‘normal-appearing white matter’ in MS patients and the white matter 
of healthy individuals. Histogram-based measures of MTR show strong 
correlation with cognitive decline in MS patients and may provide a useful 
method to study the natural course of MS or to evaluate the effect of drug 
treatments.  
  
Magnetization transfer is a unique contrast mechanism in MRI that has 
been known for the past decade. Over this period, researchers have 
characterized the underlying NMR physics, exchange and relaxation rates that 
govern MT, although detailed understanding of the chemistry and molecular 
interactions is still needed. Full models of MT have allowed for confident 
optimization of MRI pulse sequences for MT. MT has shown its value in 
42 
 
MRA and white matter disease and holds continuing promise for use in 
imaging other tissues and diseases. 
 
MATERIALS AND METHODS 
Design of the Study: Prospective  
Study Centre: Institute of Neurology and Barnard Institute of Radiology, Madras Medical College 
and Government general Hospital, Chennai-3 
Study Period: January 2009 to April 2010 
Material and selection of subjects: Consecutive patients who attended outpatient department / got 
admitted in the Institute of Neurology or in medical wards fitting into the criteria stated below. 
Inclusion criteria: Patients presenting with seizures and  a cystic ring enhancing 
lesion of Brain and with a visualized scolex in MRI as reported by 
a radiologist were grouped as Neurocysticercosis.  
Exclusion criteria: All patients with calcified granuloma 
Patients with primary malignancy 
HIV positive patients  
Patients with Claustrophobia 
 
STUDY PROCEDURE: 
Ethical Consideration: 
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 The study was commenced after obtaining approval from the Institutional Ethical 
Committee. Written informed consent was obtained from those who were willing to participate in 
the study after explaining to them about the nature of study, additional sequences of imaging and 
the need for follow up in the prescribed format and in the regional language. Left thumb impression 
was obtained from those patients who are illiterate. 
Detailed histories were obtained including the semiology of seizure, seizure clusters if any 
before presentation, treatment details before presentation, previous history of seizures and were 
entered in the pro forma. A thorough clinical examination was performed at the time of admission 
and was recorded.  
All patients were treated with anti epileptic drugs for the entire study period. A course of 
steroids of 1 mgm/kg was started on patients who had signs of increased intra cranial tension or 
imaging evidence of profound peri lesional edema.  
Patients who were already started on Tab.Albendazole for the current illness by their 
primary physicians before enrolment into this study were continued on the same for 8 days. Patient 
who were treatment naïve until enrolment in the study were not treated with Tab.Albendazole.  
No Serological or CSF tests for Neurocysticercosis were included in the study. All patients 
were followed up during the entire study period. They were asked to report for recurrence of 
seizures in addition to a monthly follow up. CT scans with contrast were done at the end of 6 
months for regression, persistence, enlargement, resolution and calcification. In patients with 
unresolved / partially resolved cysts CT scans were repeated at 12 months. Repeat CT scans were 
also planned for patients presenting with a recurrence of seizure with semiology different from that 
of the presenting one at any point during the follow up.  
All patients were imaged with MRI Brain and opinions obtained from radiologists. 
Sequences used: 
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Conventional spin ECHO T1-Weighted plain and contrast, T2-Weighted non contrast axial MR 
images. 
Ps3d/3d CISS sequence – for demonstration of scolex. 
Signal intensity from rim of the granuloma (Region of Interest) was obtained with a single pixel 
from the conventional T1WI without an off resonance pulse and MT images with an off resonance 
pulse. 
For each region of interest (ROI), Magnetisation Transfer Ratio (MTR) was calculated using the 
formula: 
MTR = (Mo – Mt)    х 100 
         Mo 
Mo – Signal intensity with saturation pulse off. 
Mt – Signal intensity with saturation pulse on. 
 
Patients with Tuberculomas were recruited and the MT ratios from their walls were calculated for 
comparison with that of the above studied Neurocysticercosis granulomas. 
Inclusion criteria for Tuberculoma: 
Patients presenting with seizures and MRI evidence of cystic ring enhancing lesions of Brain with 
coexistence at least one of the following, 
Miliary tuberculosis on chest X-ray 
Sputum positive and cavitating pulmonary tuberculosis. 
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RESULTS 
A total of 38 patients with solitary cystic Neurocysticercosis lesion with a 
visualized scolex (satisfying absolute criteria) were enrolled. 3 patients were 
lost during follow up leaving 35 patients who were studied for 12 months.  
Age distribution 
Age Incidence 
11 to 20 13 
21 to 30 9 
31 to 40 7 
41 to 50 4 
¾ 50 2 
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Seizure type 
 
N 
Partial 21 
     Rt Focal Motor 9 
     Lt Focal Motor 3 
     Rt Focal Sensory 2 
     Sensori Motor 5 
     Speech arrest 1 
     Occipital seizures 1 
Secondary Generalisation 8 
Complex partial 2 
      Cps Secondary Generalisation 1 
Generalised from Onset 12 
 
Number of seizures before presentation 
 
Number of seizures at 
presentation 
Number of 
patients 
1 9 
2 – 5 13 
6 – 10 8 
>10 5 
 
9 patients had a solitary seizure at presentation.13 patients presented with 
more than 5 / clusters of seizures and one of them presented with status 
epilepticus. 
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Location of cyst in the MRI 
LOCATION N 
Frontal 11 
Parietal 21 
Temporal - 
Occipital 3 
 
 
The lateralization and localisation of cystic granulomas in the imaging 
studies. 
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Status of the Cyst on Follow up Scans 
Patients were subjected to CT scans with contrast study around 6 and 12 
months of the study.48% of the total granulomas completely resolved and 11% 
of them calcified at 6 months. At 12 months 65% of all granulomas disappeared 
while 17 % were found calcified. At 12 months one of the patients was found to 
have a new granuloma from a site different from the initial one. This patient 
had recurrence of seizures, the semiology of which was the same as that of 
presenting one (GTCS). 
Complete Resolution of cysts at 12 months with / without 
Albendazole Treatment: 
Of the 35 patients followed up 23 patients had a complete resolution of their 
cysts at the end of 12 months 9 of the 14 patients treated with Albendazole 
and 14 of the 21 patients treated without Albendazole had a complete 
resolution. 
The complete reolution of cysts in association with Albendazole was looked 
into: 
Complete  resolution Observed N Expected N Residual 
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Calcification of cysts at 12 months with / without 
 Albendazole Treatment: 
Of the 35 patients followed up 6 patients had a calcification of their cysts at 
the end of 12 months 2 of the 14 patients treated with Albendazole and 4 of 
the 21 patients treated without Albendazole had a residual calcification. 
The calcification of cysts in association with Albendazole was looked into: 
 
Albendalole Treated 
Albendalole NOT 
Treated 
Total 
9 
14 
23 
11.5 
11.5 
-4.5 
-4.5 
 COMPLETE RESOLUTION 
Chi-Square 
Df 
p 
3.522 
1 
.061 
 
Residual calcification 
 
Observed N
 
Expected N
 
Residual 
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PREDICTORS OF SEIZURE RECURRENCE- clinical 
 
Albendalole Treated 
 
Albendalole NOT Treated
 
Total 
 
2 
 
4 
 
6 
 
4 
 
4 
 
 
 
-2.5 
 
2.0 
 
 RESIDUAL CALCIFICATION 
Chi-Square 
Df 
p 
2.000 
1 
.157 
FEATURE N SEIZURE RECURRENCE “P” 
SEX 
     MALE 
     FEMALE 
 
23 
12 
 
8 
3 
0.182 
MEDIAN AGE AT DIAGNOSIS 
     <24 
     >24 
 
16 
15 
 
7 
4 
0.257 
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ASSOSIATIONS  OF SEIZURE RECURRENCE- Follow up Radiology 
 
Of the 35 patients followed up, 11 patients had a recurrence of seizures in the 
entire follow up period. The follow up radiological study in these patients with 
recurrence of seizures showed a residual calcification in 6, partial resolution in 
4 and complete resolution of cysts in one patient at the end of 12 months  
The recurrence of seizure during the study period in association with the 
residual calcification / partial resolution at 12 months were looked into: 
TODDs PARALYSIS 11 3 0.19 
NUMBER OF SEIZURES AT 
PRESENTATION 
     <5                                                 
     >5 
 
 
21 
13 
 
 
7 
4 
0.12 
SEIZURE TYPE 
     PARTIAL 
     PARTIAL TO GEN 
     GENERALIZED 
 
13 
9 
12 
 
5 
3 
3 
0.163 
LOCATION OF CYSTS 
     PARIETAL 
     FRONTAL 
     OCCIPITAL 
 
21 
11 
3 
 
8 
3 
- 
0.184 
ANTI HELMINTHIC 
TREATMENT 
     ALBENDAZOLE TREATED 
     NOT TREATED 
 
14 
21 
 
7 
4 
0.134 
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Magnetisation Transfer Ratio: 
 
 
 
Observed N 
 
Expected N 
 
Residual 
 
Residual calcification / 
partial resolution 
 
Complete resolution 
 
Total  
 
10 
 
 
1 
 
11 
 
5 
 
 
5 
 
 
 
3.0 
 
 
-3.0 
 
 SEIZURE RECURRENCE 
Chi-Square 
Df 
p 
4.500 
1 
.034 
 
PARAMETER N 
 
Mean MT 
Ratio 
“p” 
 
Number of seizures at presentation 
          Single 
          >10 / clusters 
9 
5 
 
16.4 
15.8 
 
0.83
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The Magnetisation transfer ratio from the cyst walls of all patients was 
calculated at the time of inclusion into the study.  
 
The MT ratio of all the  patients ranged from 15.6 to 17.56. 
Despite this narrow range, the MT ratio calculated at presentation was 
tested for any association with the number of seizures (single / >10) at 
presentation, recurrences in the follow up period and complete resolution at 12 
months.  
 
Magnetisation Transfer Ratio - Neurocysticercosis and Tuberculoma: 
 
Recurrence in the follow up period 
          Yes 
          No 
11 
24 
 
16.1 
17.0 
0.54
 
Complete Resolution at 12 months 
          Yes 
          No 
23 
12 
 
15.4 
16.9 
0.34
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DISCUSSION 
The study was determined to include only the unequivocal cases of 
Neurocysticercosis. The latest consensus statement available in the literature is 
the one published following the meeting of a panel of experts in August 2000 
at Lima, Peru which states 3 absolute criteria that permit an unequivocal 
diagnosis of Neurocysticercosis. The practically feasible criterion of 
“Evidence of cystic lesions showing the scolex on CT or MRI” was chosen as 
the essential pre requisite for inclusion of patients in this study.  
 
Age and Sex incidence: 
Degenerating neurocysticercosis lesions can occur at any age; the 
youngest reported patient in literature was 2 years old. This study included 
patients between 11 and 62 years with a mean age of 24 and with a gender 
distribution of 23 males and 12 females. The above data from this study are 
compared with other similar studies. It is unclear as to why NCC is more 
common in the young adults; it might be the result of a relative lack of 
immunity to the infection at that age. With age, repeated exposure of the 
parasite might lead to some degree of immunity in the  
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Age and sex incidence in comparison with major studies 
Author 
Year 
 
Age (years) Sex 
Total 
<20 >20 M F 
Tandon and Bhargava 1985 12 10 10 12 22 
Sethi et al 1985 5 6 7 4 11 
Goulatia et al 1987 Mean 16.4 24 22 46 
Wadia et al 1987 18 21 - - 39 
Van Dyck 1988 5 0 3 2 5 
Bhatia and Tandon 1988 17 8 19 6 25 
Ahuja et al 1989 - - 16 22 38 
Kumar et al 1990 56 0 - - 56 
Sachdev et al 1991 20 1 - - 20 
Chopra et al 1992 74 48 77 45 122 
Misra et al 1994 - - - - 513 
Murthy and Reddy 1998 Mean  21.9 68 34 102 
V.rajashekar et al 2001 Mean 20.8 129 81 210 
Goel.D 2010 Mean 21.4 244 101 345 
This study 2010 Mean 24.1 23 12 35 
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individual which prevents the development of disease even if the individual 
consumes ova or parasite. The higher predilection of males in many of the 
series including this could be because of the fact that men are more likely to 
consume foods prepared outside their homes. Foods prepared outside the 
home might not be hygienically prepared and stored and the chances of 
several people handling then are high. 
 
Seizure types at presentation: 
Partial seizures are by far the commonest presentations in all the studies  to the 
magnitude of 100% in Kumar et al and Wadia et al studies and above 90% in 
the studies of Tandon,Bhatia and Sachdev.  
This study also revealed partial seizures as the most common type (60%) of 
which 40% generalised.Among the partial seizures right focal motor 
semiology was the commonest observed. The high percentage generalisation 
from onset (35%) is similar to the one observed in Chopra et al study. One 
patient had speech arrest as the only neurological presentation. The rare 
occurrence of complex partial seizures is a similar observation in most of the 
cited studies. The commonest sites of lesion location in this study were in the 
parietal lobes as in most of the studies.  
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Seizure types in comparison with major studies 
Author  
Year 
 
Simple 
Partial 
Complex 
partial 
Generalised 
From onset 
Others Total 
Tandon and Bhargava 1985 14 1 1 - 16 
Sethi et al 1985 9 - 2 - 11 
Goulatia et al 1987 38 - 6 2 46 
Wadia et al 1987 39 - - - 39 
Bhatia and Tandon 1988 16 - 4 - 20 
Kumar et al 1990 56 - - - 56 
Sachdev et al 1991 19 - 1 - 20 
Chopra et al 1992 86 4 31 1 122 
Srinivas et al 1994 23 - 7 - 30 
Sethi et al 1995 164 5 17 - 186 
Del Brutto 1995 37 - 17 - 54 
Murthy and Reddy 1998 15 49 13 25* 102 
This study 2010 21 2 12 - 35 
* Simple or complex partial with secondary generalization  
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RECURRENCE OF SEIZURES: 
The arbitrary “window period” 
The recurrences of seizures as defined in the other similar studies were 
the one following a window period of 1 week following the first seizure. This 
is in accord with strategies used for classification of acute symptomatic 
seizures from other causes51 such as stroke or head injury. In 
Neurocysticercosis, the seizures that occur both in the so called window 
period as well as in the early months (the periods of maximal recurrences) are 
due to an ongoing activity in the cysts and hence this situation is not 
comparable to strokes and head injuries in stratification of the window period. 
Despite being arbitrary, the window period defined for recurrence in this study 
too was 1 week in accordance with other similar studies22. 
Seizures recurred in 11 of the 35 patients (31%) of patients in the follow 
up period of 12 months. This seizure recurrence rate of 31% in this study is 
also in the same range as that of the recurrence rate observed among 
individuals with structural brain abnormalities and acute symptomatic seizures 
53, 54, 55, 56, 57.  A similar study of solitary Neurocysticercosis granuloma from 
Ecuador by Carpio and Hauser52 is compared below for the cumulative seizure 
recurrences in relation to the follow up period.  
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Follow up period 
Cumulative Seizure recurrence (%) 
This Study Carpio and Hauser 
At 6 months 27.4% 22% 
At 12 months 31% 32% 
 The cumulative seizure recurrence in this study was a marginal 5% high at 3 
months period but was almost similar at 12 months compared to Carpio and 
Hauser study, which included twice as many patients as that of this study.  
A total of 14 seizures occurred among this 11 patients. The semiology 
of recurrences in all patients was the same as that of the initial ones which 
implies that the same lesions were the ones causing recurrences.  
Associations of seizure recurrence:  
The cause for only a group of patients developing recurrences, 11 out of 
35 patients as in this study is an issue of intensive research and postulations. 
Knowledge of the risk of seizure recurrence is a necessary prerequisite for 
making rational decisions regarding short-term treatment of the acute 
condition and the need for long-term treatment with antiepileptic drugs 
(AED).An array of variables from patients with and without seizure 
recurrences in this study were analyzed for their potential associations with 
recurrence (Table following) and the only  
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Feature N 
Seizure  
recurrence 
“p” 
Sex 
     male 
     female 
 
23 
12 
 
8 
3 
0.182 
Median age at diagnosis 
     <24 
     >24 
 
16 
15 
 
7 
4 
0.257 
Todds paralysis 11 3 0.19 
Number of seizures at presentation 
     <5                                                               
     >5 
 
 
21 
13 
 
 
7 
4 
0.12 
Seizure type 
     partial 
     partial to gen 
     generalized 
 
13 
9 
12 
 
5 
3 
3 
0.163 
Location of cysts 
     parietal 
     frontal 
     occipital 
 
21 
11 
3 
 
8 
3 
- 
0.184 
Anti helminthic treatment 
     albendazole treated 
     not treated 
 
14 
21 
 
7 
4 
0.134 
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parameter associated significantly (p=0.034) was the persistence of 
abnormalities at 12 months CT scan (partial resolution / calcification). This 
implies that patients with either partial resolution or calcification in their 
repeat scans at 12 months period need a longer anti epileptic course than the 
other group of patients. A number of studies have found correlations between 
the persistence of viable or degenerating cysts and increased risks of 
seizures58, 59, and 60 
Seizure Recurrence in Albendazole treated and untreated groups: 
The studies on effectiveness of antiparasitic treatments in solitary 
degenerating NCC have been variable. 
 A non blinded follow-up evaluation of Albendazole treated and non 
treated subjects by Baranwal AK et al63 showed an equalization of seizure 
frequency and an overall good prognosis in both groups. This study followed 
patients over a 2 year period. 
 In 2006 a Meta analysis of treatment trials of enhancing NCC lesions 
by Del Bruto and Garcia et al showed an overall benefit of 
treatment64including that of risk of seizure recurrences.  
This study though of a small sample size and a short follow up period 
did not show any association between seizure recurrence in patients with or 
without Albendazole treatment (p=0.134). 
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Follow up Radiology: 
There is a wide variation in the rates of complete resolution mentioned 
by different authors65 – 69, ranging from 22% to 100% at 6 months / 12 months 
after the first CT scan. 
In this study the follow up contrast CT revealed a complete resolution 
of 17 cysts (48%) at 6 months and 23cysts (65%) at 12 months.  
 
Study 
Number of patients 
followed 
Follow up 
period 
Complete 
resolution (%) 
V.Rajashekar 210 6   months 
12 months 
24 months 
36 
62 
88 
Garg & Nag 101 6   months 84 
Jain et al 156 6   months 53 
Goel et al 345 6   months 61 
This study 35 6   months 
12 months 
48 
65 
 
The rates of resolution of cysts at 6 months in studies from north India are 
high compared to this study. The rate of resolution of cysts in this study was 
similar to that of the Vedantam Rajshekhar et al study. 
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Timing of the follow-up scan: 
Patients with solitary NCC have a good seizure prognosis after withdrawal of 
antiepileptic drugs soon after the resolution of the granuloma70, 1. Hence it is 
important to know the natural history of a solitary NCC to decide on the 
timing of the follow-up scan after the initial investigation. From the trends of 
resolution (near about 50% resolve in 6 months) in this study it is reasonable 
to repeat imaging studies at 6 months. The caveat to this statement is that the 
patient should be clinically evaluated frequently to look for symptoms and 
signs of a progressive lesion. 
It is mentioned in a few studies, as the one by Mukherjje et al that in a 
small proportion of cases (10%), the cysts actually increase in size on follow-
up CT scans. No such phenomenon was observed in this study. 
Complete Resolution of cysts at 12 months with / without Albendazole 
Treatment: 
Of the 35 patients followed up 23 patients had a complete resolution of their 
cysts at the end of 12 months 9 of the 14 patients treated with Albendazole 
and 14 of the 21 patients treated without Albendazole had a complete 
resolution. The association of complete resolution with / without Albendazole 
treatment was not statistically  significant.  
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Disappearance and reappearance of cysts: 
 
One patient in this study had a recurrence of granuloma at a site other 
than the presenting one in the last quarter of the study. The initial one was in 
the right parietal lobe which had  resolved completely in the CT scan  taken at 
6 months and the recurrence was in the right frontal lobe. The initial as well as 
the recurrent seizure in this patient was a Generalised clonic seizure. This 
phenomenon of disappearance and reappearance of cystic as well as calcified 
granulomas at sites different from the initial one have been described in earlier 
studies from our institute by Prof.S.Kalyanaraman followed by others. 
 
`Residual calcifications:  
Among the 11 patients with seizure recurrences, 6 had calcifications (54.5%), 
4 had partial resolution (36%) and one patient (9%) had complete resolution of 
granulomas in the CT scans done at 12 months. The high incidence of calcific 
lesions among patients with recurrences is an observation differing from other 
studies52.This has implications for the following reasons.  
• Calcified brain lesions typical of those in patients with 
Neurocysticercosis are commonly seen in CT images of patients who 
present with seizures in our regions. 
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• In population-based studies that report the findings of CT examinations, 
calcified lesions are much more common than are viable cysts and they 
are more prevalent in symptomatic patients than they are in 
asymptomatic patients62.  
• Lastly, when symptoms appear in individuals with only calcified 
lesions, some of these patients have perilesional brain oedema around 
one or more of the calcifications62. 
 
Magnetisation Transfer ratio: 
The Magnetisation transfer ratio from the cyst wall of the 
neurocysticercosis granuloma at the time of inclusion in ranged from 18.4 to 
22.90. Despite being in a narrow range the variation in ratios between patients 
were analyzed statistically for any associations with an array of variables. 
None of the variables such as multiplicity of seizures at presentation, location 
of cysts, seizure recurrence and resolution of cysts had any statistical 
associations with the magnetization transfer ratios. 
The Magnetisation transfer ratios from the cyst walls of Tuberculoma 
patients selected as per the inclusion criteria ranged from 14.6 to 19.3. The 
observed MT ratios from the walls of Tuberculomas are in a lesser range 
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observed in the study by Rakesh.K.Gupta84 which ranged from 18.67 to 
23.34. 
In this study the MT ratios from walls of degenerating 
Neurocysticercosis were in a fairly distinct range compared to 
Tuberculomas.However the MT ratios of two of the NCC cysts and one of the 
Tuberculomas were observed in an overlapping range. 
Using MT ratio the sensitivity for differentiating Tuberculoma and 
NCC was 78% and specificity was 73% in this study. 
The unresolved management issue: 
Carpio and colleagues studied 138 patients prospectively with cystic 
neurocysticercosis in an open-label study of steroids alone or together with 
either albendazole or praziquantel80. Overall, there were no 
significant differences in the proportion of patients free of cysts at 6 months or 
1 year, in the proportion free of seizures for 2 years, or in the rates of 
sequelae.  
Among many case series only three randomized, controlled trials of 
Albendazole have been reported on patients with single enhancing lesions. 
Two studies (Padma, M. V et al and Singhi, P et al) demonstrated no 
significant difference in radiographic resolution69, 82. The other (Baranwal) 
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demonstrated more rapid resolution with albendazole but no significant 
difference in the frequency of clinical events83. 
In this study the treatment with Albendazole when subjected to 
statistical analysis did NOT “reduce the incidence of recurrent seizures” 
or “shorten the time to cyst disappearance.” 
The proponents of Albendazole treatment accept the above facts that 
have already been brought out in other studies but argue that they treat to kill 
larvae and  live cysts seen or not seen on neuroimaging73, 74 which if not 
treated will eventually become inflammatory and symptomatic. They also 
believe that such therapy may reduce the chance of calcification in the lesions 
during healing75. 
In contrary the number of calcifications in this study, though not statistically 
significant (p=0.157) occurred  more in the Albendazole treated group.  The 
studies of Hauser et al also do not support the argument that antihelminthic 
treatment reduces calcification. 
The non advocators of the use of antihelminths are aware that such 
therapy results in death and resolution of viable cysts, 76-79 but question the 
clinical benefit of this treatment50.They argue that the antihelminthic  
treatment predictably injures cysts and initiates at times an intense 
inflammatory response81 that mimics the natural evolution of cysts. Seizures, 
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headaches, and uncommonly death can occur secondary to cysticidal 
treatments. 
There are some conservative groups which use Albendazole only when 
cysts do not regress after 6 months, in enlarging cysts, and in a few patients 
with “disappearing/reappearing” lesions. 
Evidence for a convincing clinical outcome from more trials of 
anticysticercal treatment is keenly awaited. 
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CONCLUSIONS 
 
1. The observed mean age of incidence of single ring enhancing 
Neurocysticercosis was 24 with a male female ratio of 2:1. 
2. Partial seizures were the most common seizure type at presentation of 
which right focal motor semiology was the commonest. 
3. Majority of granulomas occurred in the parietal lobes (Left > Right). 
4. Seizures recurred in 11 of the 35 patients (31%)  in the follow up 
period of 12 months. 
5. Follow up contrast CT revealed a complete resolution of 17 cysts 
(48%) at 6 months and 23cysts (65%) at 12 months. 
6. Treatment with Albendazole did NOT statistically “reduce the 
incidence of recurrent seizures” or “shorten the time to cyst 
disappearance.” 
7. The only parameter associated with seizure recurrence statistically 
(p=0.034) with was the persistence of abnormalities at 12 months CT 
scan (partial resolution / calcification). 
8. The high incidence of a resultant calcific lesions among patients with 
recurrences is an observation different from other studies. 
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9. The Magnetisation transfer ratio from the cyst wall of the 
neurocysticercosis granuloma at the time of inclusion in ranged from 
18.4 to 22.90. 
10. MT ratio differentiated Tuberculoma and degenerating NCC with a 
sensitivity of 78%, and specificity of 73%. 
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PROFORMA FOR EVALUATION  
     Name                                                       age                            sex  
 
     Address  
 
 
      Occupation                                                                Contact no  
      
     Medical unit  prof            op/ip no                  ward              DOA                    DOD        
 
     Neuro unit prof                 min no                    EEG no    
 
     Referred from 
 
 
  Elaboration of seizure  
      
     Witnesse of seizure                                                                                Reliability  
 
     Before the episode  
     Recent illness (headache / fever ) 
 
     Unusual stress  
     Medications 
     Last alcohol intake  
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     Last meal    
     Sleep deprivation  
     Activity just before seizure  
 
     During the episode  
     Time of day  
     Aura  
     Duration  
     Ability to talk & comprehend  
     Ability to recall events  
     Movements of      eyes                  face                arms                  legs  
     Tongue bite                                           frothing 
     Bowel / bladder incontinence  
     Bodily injuries sustained  
 
     After event 
     Confusion                          duration 
     Focal neurological deficits    
 
     Headache 
     Any other significant symptoms 
 
     SIGNIFICANT PAST HISTORY 
      
     Diabetic : yes / no      duration & treatment 
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     Hypertension                                              CAD                                 CKD 
     tuberculosis  
     any others 
 
      
      
     alcohol intake  y / n       duration                freq                  quantity 
     last intake 
     smoking  
      
 
 
 
     family h/o seizures  
 
     Clinical Examination       
     General exam      
 
      Neuro cut markers  
     Vitals :    BP              Pulse            RR              Temp 
 
     CNS  :      
     at presentation                                Time after seizure   
     signs of meningial irritation   
     higher functions  
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     motor system  
 
 
     sensory system                                     
     cranial nerves 
     
     cerebellum         
     CVS :                                        RS:                                         P/A : 
      
      
       
     COURSE DURING HOSPITAL STAY 
 
 
 
 
 
 
 
 
 
 
 
  INVESTIGATIONS :  
      
       Hematology       TC :         DC:     P   L   E   B            HB :         ESR:  
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       Biochemistry     sugar             urea          creatinine              Na          k        Ca   
 
        
        
       Others : 
 
 
 
 
      
      CXR   : 
      
 
      
     CT BRAIN: 
 
 
     MRI BRAIN:  
 
 
    
 
 
 
     Treatment  
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MASTER CHART 
Patient  
Number 
Age  Sex  Seizure 
Semiology 
Number of 
seizures at 
presentation 
Location 
Of cyst  
Alb  Recurren
1.   13 M  GO 2 ‐ 5 F  Y R
2.   25 F  PG >10 PA  N R
3.   39 M  P 6 ‐ 10 O  N NR
4.   23 M  GO 1 F  Y NR
5.   17 M  CPG 1 PA  N NR
6.   21 M  P >10 F  N R
7.   14 M  GO 2 ‐ 5 F  Y N R
8.   28 F  P 1 F  N NR
9.   18 F  GO 2 – 5 PA  Y R
10. 13 M  PG 1 PA  Y NR
88 
 
11. 19 F  P 6 ‐ 10 PA  N NR
12. 40 F  P 6 ‐ 10 PA  N NR
13. 39 M  P 1 PA  N NR
14. 16 M  P >10 PA  N R
15. 23 F  GO 2 ‐ 5 PA  Y NR
16. 41 M  P 6 ‐ 10 F  N R
17. 38 M  GO 2 ‐ 5 PA  Y NR
18. 18 F  GO 2 – 5 O  N NR
19. 27 M  PG 2 – 5 PA  N NR
20. 19 M  P 2 – 5 PA  Y R
21. 33 F  PG 6 ‐ 10 PA  N NR
22. 47 M  GO 1 PA  Y NR
23. 24 M  GO >10 PA  N R
24. 40 F  CP 2 – 5 PA  N NR
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25. 15 M  PG 6 ‐ 10 PA  Y NR
26. 64 M  P 2 – 5 F  N R
27. 32 M  GO 6 ‐ 10 O  N NR
28. 24 F  PG 1 F  Y NR
29. 17 M  GO 2 – 5 PA  Y R
30. 19 F  GO >10 PA  N NR
31. 38 M  PG 1 PA  Y NR
32. 28 F  P 6 ‐ 10 F  N NR
33. 33 M  P 2 – 5 PA  N NR
34. 11 M  P 1 F  N NR
35. 60 M  PG 2 ‐ 5 PA  Y NR
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